Evidence map›Paper›PMID 35042460›Full record

ArticleBMC cancer2022

HoSAGE: sarcopenia in older patient with intermediate / high-risk prostate cancer, prevalence and incidence after androgen deprivation therapy: study protocol for a cohort trial.

Anne-Laure Couderc, Patrick Villani, Julie Berbis, Emilie Nouguerède, Dominique Rey, Dominique Rossi, Éric Lechevallier, Delphine Badinand, Cyrille Bastide, Gilles Karsenty and 3 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04484246 (Evaluation of the Incidence and Prevalence of Sarcopenia in Patients 70 Year and Older With Localized and Locally Advanced Porstate Cancer, Treated by Radiotherapy and Androgen Deprivation Therapy. a Monocentric Cohort Trial), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04484246 completednot on this map

Evaluation of the Incidence and Prevalence of Sarcopenia in Patients 70 Year and Older With Localized and Locally Advanced Porstate Cancer, Treated by Radiotherapy and Androgen Deprivation Therapy. a Monocentric Cohort Trial

TypeobservationalSponsorAssistance Publique Hopitaux De MarseilleRan2019 to 2023Enrolled112ConditionsProstate CancerArmsPrevalence of sarcopenia in older patient with prostate cancer
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Anne-Laure CoudercInternal Medicine, Geriatrics and Therapeutic Unit, Sainte-Marguerite Hospital, AP-HM, 270 Boulevard Sainte Marguerite, 13009, Marseille, France. anne-laure.couderc@ap-hm.fr.ORCID http://orcid.org/0000-0003-2938-2201
Patrick VillaniInternal Medicine, Geriatrics and Therapeutic Unit, Sainte-Marguerite Hospital, AP-HM, 270 Boulevard Sainte Marguerite, 13009, Marseille, France.
Julie BerbisEpidemiology and Health Economics Unit, La Timone Hospital, AP-HM, 13385, Marseille, cedex 05, France.
Emilie NouguerèdeInternal Medicine, Geriatrics and Therapeutic Unit, Sainte-Marguerite Hospital, AP-HM, 270 Boulevard Sainte Marguerite, 13009, Marseille, France.
Dominique ReyInternal Medicine, Geriatrics and Therapeutic Unit, Sainte-Marguerite Hospital, AP-HM, 270 Boulevard Sainte Marguerite, 13009, Marseille, France.
Dominique RossiUrological Surgery Unit, Nord Hospital, AP-HM, Chemin des Bourrely, 13915, Marseille, cedex 20, France.
Éric LechevallierUrological Surgery and Renal Transplantation Unit, Conception Hospital, AP-HM, 147 Boulevard Baille, 13005, Marseille, France.
Delphine BadinandRadiotherapy Unit, Timone Hospital, AP-HM, 264 Rue Saint Pierre, 13385, Marseille, cedex 05, France.
Cyrille BastideUrological Surgery Unit, Nord Hospital, AP-HM, Chemin des Bourrely, 13915, Marseille, cedex 20, France.
Gilles KarsentyUrological Surgery and Renal Transplantation Unit, Conception Hospital, AP-HM, 147 Boulevard Baille, 13005, Marseille, France.
Romain BoissierUrological Surgery and Renal Transplantation Unit, Conception Hospital, AP-HM, 147 Boulevard Baille, 13005, Marseille, France.
Kahena AmichiDirection de la Recherche Clinique et de l'Innovation (DRCI), Assistance Publique des Hôpitaux de Marseille (AP-HM), 80 Rue Brochier, 13354, Marseille, Cedex 05, France.
Xavier MuraccioleRadiotherapy Unit, Timone Hospital, AP-HM, 264 Rue Saint Pierre, 13385, Marseille, cedex 05, France.
Aix-Marseille Université · FRHôpital de la Timone · FRCentre National de la Recherche Scientifique · FRHôpital Sainte-Marguerite · FRAssistance Publique Hôpitaux de Marseille · FR

Funding

Assistance publique-Hôpitaux de Marseille Not applicable
6 · The paper itself

Abstract

backgroundSarcopenia is defined by a loss of muscle strength associated to a decrease in skeletal muscle mass. Ageing greatly contributes to sarcopenia as may many other factors such as cancer or androgen deprivation therapies (ADT). This cohort study aims to evaluate (1) the prevalence of muscle disorders and sarcopenia in older patients before initiation of intermediate to high risk prostate cancer treatment with ADT and radiotherapy, and (2) the occurrence and/or aggravation of muscle disorders and sarcopenia at the end of cancer treatment.

methodsThis cohort study is monocentric and prospective. The primary objectives are to determine the risk factor of sarcopenia prevalence and to study the relationship between ADT and sarcopenia incidence, in patients 70 years and older with histologically proven localized or locally advanced prostate cancer, addressed to a geriatrician (G8 score ≤14) for comprehensive geriatric assessment (CGA) in Marseille University Hospital. Secondary objectives encompass, measurement of sarcopenia clinical criteria along prostate oncological treatment; evaluation of the quality of life of patients with sarcopenia; evaluation of the impact of socio-behavioral and anthropological factors on sarcopenia evolution and incidence; finally the evaluation of the impact of ADT exposure on sarcopenia. Sarcopenia prevalence was estimated to be between 20 and 30%, therefore the study will enroll 200 patients. DISCUSSION: The current guidelines for older patients with prostate cancer recommend a pelvic radiotherapy treatment associated to variable duration (6 to 36 months) of ADT. However ADT impacts muscle mass and could exacerbate the risks of sarcopenia. Our study intends to assess the specific effect of ADT on sarcopenia incidence and/or worsening as well as to estimate sarcopenia prevalence in this population. The results of this cohort trial will lead to a better understanding of sarcopenia prevalence and incidence necessary to further elaborate a prevention plan.

trial registrationThe protocol was registered to the French drug and device regulation agency under the number 2019-A02319-48, before beginning the study (11/12/2019). The ClinicalTrials.gov identifier is NCT04484246, registration on the ClinicalTrials.gov ( https://clinicaltrials.gov/ct2/show/NCT04484246 ).

Indexed as

AgedAndrogen AntagonistsAntineoplastic Agents, HormonalGeriatric AssessmentHumansIncidenceMaleMuscle StrengthPrevalenceProspective StudiesProstatic NeoplasmsQuality of LifeRisk FactorsSarcopeniaAndrogen AntagonistsAntineoplastic Agents, Hormonalandrogen deprivation therapyincidenceolder patientprevalenceprostate cancerradiotherapySarcopenia

Identifiers

PMID35042460
PMCPMC8764762
OpenAlexW4206088672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.